CG Oncology (CGON) Shares Outstanding (Weighted Average) (2023 - 2026)

CG Oncology (CGON) has 4 years of Shares Outstanding (Weighted Average) data on file, last reported at $84.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 10.93% year-over-year to $84.5 million; the trailing twelve-month figure through Mar 2026 stood at $84.5 million (up 10.93% YoY), and the FY2025 full-year result was $77.3 million, up 23.69% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $84.5 million, up from $77.3 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $84.5 million in Q1 2026 and bottomed at $3.9 million in Q1 2023.
• The 4-year median for Shares Outstanding (Weighted Average) is $62.5 million (2024), against an average of $49.5 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) soared 1600.89%; it then increased 10.93% in 2026.
• A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $4.3 million in 2023, then surged by 1343.03% to $62.5 million in 2024, then rose by 23.69% to $77.3 million in 2025, then increased by 9.33% to $84.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $84.5 million (Q1 2026), $77.3 million (Q4 2025), and $76.4 million (Q3 2025), per Business Quant data.

Peer Comparison